In people at risk for MASLD (those who are very overweight or obese or have diabetes, high blood pressure, and abnormal ...

A protein that stops cells from dividing in response to damage or stress could be a new biomarker or therapeutic target for ...

Researchers predict a steady increase in fatty liver disease in the U.S. population, but there's not a lot of treatment ...

MASLD, previously called ‘fatty liver disease’, is a ticking timebomb, affecting 30 to 40 per cent of adults – most of whom ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

Data from a meta-analysis of 8 observational studies accounting for more than 26 million people across the globe were ...

Unlike liver disease linked to alcohol abuse, MASLD is driven largely by metabolic imbalances, poor diet and sedentary ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated ...

89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate ...

April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage ...